Scholarly Articles for the week of July 31, 2023

  1. #chatsafe 2.0. updated guidelines to support young people to communicate safely online about self-harm and suicide: A Delphi expert consensus study. Robinson J, Thorn P, McKay S, Hemming L, Battersby-Coulter R, Cooper C, Veresova M, Li A, Reavley N, Rice S, Lamblin M, Pirkis J, Reidenberg D, Harrison V, Skehan J, La Sala L.PLoS One. 2023 Aug 2;18(8):e0289494. doi: 10.1371/journal.pone.0289494. eCollection 2023. PMID: 37531397
  2. Changing cancer mindsets: A randomized controlled feasibility and efficacy trial. Zion SR, Schapira L, Berek JS, Spiegel D, Dweck CS, Crum AJ. Psychooncology. 2023 Aug 2. doi: 10.1002/pon.6194.   PMID: 37529924
  3. Barriers to Receiving Follow-up Care Among Childhood Cancer Survivors. Bossert S, Borenzweig W, Benedict C, Cerise JE, Siembida EJ, Fish JD. J Pediatr Hematol Oncol. 2023 Jul 20. doi: 10.1097/MPH.0000000000002714.   PMID: 37526350
  4. Does the advent of depot therapy represent a step change in our understanding of opioid use disorder and its treatment? Roberts E, Humphreys K. Drug Alcohol Rev. 2023 Jul 31. doi: 10.1111/dar.13732.   PMID: 37525510
  5. Anxiety, concerns and COVID-19: Cross-country perspectives from families and individuals with neurodevelopmental conditions. Sideropoulos V, Van Herwegen J, Meuleman B, Alessandri M, Alnemary FM, Rad JA, Lavenex PAB, Bolshakov N, Bölte S, Buffle P, Cai RY, Campos R, Chirita-Emandi A, Costa AP, Costanzo F, Des Portes V, Dukes D, Faivre L, Famelart N, Fisher MH, Gamaiunova L, Giannadou A, Gupta R, Hardan AY, Houdayer-Robert F, Hrncirova L, Iaochite RT, Jariabkova K, Klein-Tasman BP, Lavenex P, Malik S, Mari F, Martinez-Castilla P, Menghini D, Nuske HJ, Palikara O, Papon A, Pegg RS, Pouretemad H, Poustka L, Prosetzky I, Renieri A, Rhodes SM, Riby DM, Rossi M, Sadeghi S, Su X, Tai C, Tran M, Tynan F, Uljarević M, Van Hecke AV, Veiga G, Verloes A, Vicari S, Werneck-Rohrer SG, Zander E, Samson AC. J Glob Health. 2023 Jul 28;13:04081. doi: 10.7189/jogh.13.04081. PMID: 37497751 
  6. Promises and perils of the FDA's over-the-counter naloxone reclassification. Zhu DT, Tamang S, Humphreys K. Lancet Reg Health Am. 2023 May 22;23:100518. doi: 10.1016/j.lana.2023.100518. eCollection 2023 Jul. PMID: 37497396 
  7. Transcutaneous Vagus Nerve Stimulation (tVNS) applications in cognitive aging: a review and commentary. Naparstek S, Yeh AK, Mills-Finnerty C. Front Aging Neurosci. 2023 Jul 11;15:1145207. doi: 10.3389/fnagi.2023.1145207. eCollection 2023. PMID: 37496757 
  8. Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1. Dauvilliers Y, Mignot E, Del Río Villegas R, Du Y, Hanson E, Inoue Y, Kadali H, Koundourakis E, Meyer S, Rogers R, Scammell TE, Sheikh SI, Swick T, Szakács Z, von Rosenstiel P, Wu J, Zeitz H, Murthy NV, Plazzi G, von Hehn C. N Engl J Med. 2023 Jul 27;389(4):309-321. doi: 10.1056/NEJMoa2301940. PMID: 37494485 

By Category

Additional Topics